DURHAM–Inspire Pharmaceuticals (Nasdaq:ISPH) said its scientists and collaborators will present data from five research abstracts at the Association for Research in Vision and Ophthalmology (ARVO) meeting April 25-29 in Ft. Lauderdale, Florida.

The abstracts include data from Inspire’s Phase III clinical studies of its experimental dry eye treatment and on retinal detachment and reattachment.

This week, Inspire launched its most recent clinical trial, a study of a new drug treatment for the most common type of detached retina, which is currently usually treated by surgery.